Disclosed are thiadiazine compounds, derivatives and compositions thereof. The compounds, derivatives, and compositions can be used for treating or preventing a heat-shock protein responsive disorder or suppressing protein aggregation in a subject. The compounds and compositions can also be used for treating cancer, neurodegenerative disorders, and other heat-shock protein responsive disorders.

Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds. ##STR00001##

Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds. ##STR00001##

The present invention provides a novel compound that has anti-RSV activity and that is useful in the prevention or treatment of an infection in which viruses of the subfamily Pneumovirinae, including respiratory syncytial virus (RSV), are involved, or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof.

A series of new macrocycles and cage-like molecules are obtained in a high yield from a bis-(2,4-dialkoxyphenyl)arene (naphthalene, anthracene, pyrene, porphyrin, etc.) or a tris-(2,4-dialkoxyphenyl)arene (benzene, sym-tribenzobenzene) and paraformaldehyde under the catalysis of a Lewis acid. In addition, perhydroxybiphenylarenes (tetrabiphenyl trimer, naphthalene dimer, etc.) can be obtained by means of demethylation, and a variety of water-soluble derivatives can be obtained by further modification, with same exhibiting a good bond ability for guest molecules (purpurine, etc.). Moreover, the functional group introduced into the backbone enables the macrocycle to have excellent adsorption and separation capabilities and a photophysical property. The macrocyclic and cage-like molecules have commercially available raw materials, are simple to synthesize, have a high yield, and are convenient to modify, such that same have wide application prospects in gas adsorption and separation, facilitate performance improvement of luminescent materials, perform adsorption of water-soluble toxic substances, etc.

A series of new macrocycles and cage-like molecules are obtained in a high yield from a bis-(2,4-dialkoxyphenyl)arene (naphthalene, anthracene, pyrene, porphyrin, etc.) or a tris-(2,4-dialkoxyphenyl)arene (benzene, sym-tribenzobenzene) and paraformaldehyde under the catalysis of a Lewis acid. In addition, perhydroxybiphenylarenes (tetrabiphenyl trimer, naphthalene dimer, etc.) can be obtained by means of demethylation, and a variety of water-soluble derivatives can be obtained by further modification, with same exhibiting a good bond ability for guest molecules (purpurine, etc.). Moreover, the functional group introduced into the backbone enables the macrocycle to have excellent adsorption and separation capabilities and a photophysical property. The macrocyclic and cage-like molecules have commercially available raw materials, are simple to synthesize, have a high yield, and are convenient to modify, such that same have wide application prospects in gas adsorption and separation, facilitate performance improvement of luminescent materials, perform adsorption of water-soluble toxic substances, etc.

Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.